PYCARD (PYD And CARD Domain Containing)

These findings indicate that reduced NLRP3 expression is associated with unfavorable prognosis in TNBC. Although exploratory in nature, this study highlights the potential relevance of inflammasome components as prognostic biomarkers in this aggressive breast cancer subtype and warrants further validation in independent cohorts.

We delineated the PANoptosis landscape in ccRCC and developed a robust PRG score with strong prognostic and immunological relevance. RBCK1 functions as a key oncogenic regulator and potential therapeutic target. These findings offer a valuable framework for precision risk assessment and treatment optimization in ccRCC.

Structural characterization identified nine high-impact nsSNPs (ΔΔG <  - 1.7 kcal/mol), particularly in TLR3 (L104N, L381P, L77P) and CD274 (W57S, C155S, G159D, Y112N), indicating potential disruption of receptor stability, immune checkpoint interactions, and inflammasome regulation. This integrative multi-omics and structural pharmacogenomics framework reveals a robust four-gene signature (CASP1, TLR3, PYCARD, CD274) that links necroptosis, ferroptosis, and immune modulation in BRCA, providing promising avenues for precision oncology and therapeutic target development.

We have elucidated the role of MRGs in the pathogenesis of HTN and developed a diagnostic model with high diagnostic potential.

Besides, the upstream TF network of the 7 differentiated expressed pyroptosis-related key genes was constructed. Our team developed a diagnostic model for pyroptosis-related signatures in Alzheimer's disease, investigating ceRNA and TF regulatory networks, which may facilitate the diagnosis of AD with blood-based biomarkers.

We revealed a positive correlation between the Nscore and macrophage M1, suggesting potential drug response mechanisms. Based on the identified AML subtypes and their distinct mutational landscapes, we predicted potential treatment options, with Paclitaxel, Afuresertib, and Mitoxantrone emerging as potential therapeutic agents for the AML subtypes.

Further, the results indicated that THC and CBD selectively suppress monocyte interleukin 1β production, though THC is more efficacious, through its maturation, as evidenced by suppressed caspase-1 activity and apoptosis-associated speck-like protein-incorporating inflammasome formation. This work provides evidence to support that THC, and to an extent CBD, exert anti-inflammatory effects that could be useful in mitigating monocyte interleukin 1β-mediated chronic inflammation.

This study elucidated the relationship between the development of BC and mechanisms of cellular senescence, apoptosis, and immunity. It clarified the roles of 27 genes associated with cellular senescence in BC and predicted that Triethyl phosphate, Regorafenib, Ponatinib, Lenvatinib, Nintedanib, and Quercetin may be key drugs or compounds for the treatment of BC.

Additionally, AiiO-AIO6 alleviated intestinal apoptosis, demonstrated by reduced gene expressions of pro-apoptotic genes apoptotic protease activating factor-1, Bcl-2 associated X protein, Fas ligand, and caspase-3, as well as c-Jun N-terminal kinase and mitogen-activated protein kinase p38, and elevated gene expressions of anti-apoptotic factors, B-cell lymphoma-2, myeloid cell leukemia 1, and inhibitor of apoptosis protein. Altogether, optimal levels of AiiO-AIO6 attenuated intestinal inflammation probably relating to down-regulated NF-κB signaling, and reduced NLRP3 and GSDME-mediated pyroptosis, and finally reduced apoptosis in the intestine of grass carp.

CASP1, NLRP3, AIM2, and NLRP1 are core pyroptotic genes in lung adenocarcinoma and exhibit a strong correlation with immune cell infiltration, diagnosis, and prognosis of this condition. These genes may be useful in the clinical diagnosis and treatment of patients with lung adenocarcinoma.

The hypermethylation of BRCA1 and GSTP were independent predictors of DFS, while PTEN hypermethylation was an independent predictor of OS in the TNBC cohort. The identification of hypermethylated genes, such as BRCA1, CCND2, CDH1, ESR1, GSTP, RASSF1, SLIT2, MGMT, and PTEN may serve as potential biomarkers or therapeutic targets for TNBC.

The activator RO8191 or inhibitor ruxolitinib of the JAK/STAT pathway was employed to confirm whether IKZF1 inhibited colon cancer development by regulating JAK2/STAT5 pathway...Furthermore, upregulation of IKZF1 promoted M1 macrophage polarization while inhibiting M2 macrophage polarization in vivo and in vitro by inhibiting the JAK2/STAT5 signaling pathway. This study identifies IKZF1 as a potential biomarker inactivating JAK2/STAT5 pathway for colon cancer.